Ipratropium Enfants Unidose Teva (Ipratropium Bromide Monohydrate)

Ipratropium bromide is a bronchodilator that acts on muscarinic receptors to relieve airway narrowing in several respiratory conditions.

• Asthma (children): reduces bronchoconstriction and improves breathing in pediatric patients.
• Chronic obstructive pulmonary disease (COPD): provides maintenance bronchodilation to ease airflow limitation.
• Bronchospasm: rapidly relaxes airway smooth muscle during acute episodes.

• Ipratropium bromide competitively antagonizes muscarinic (M3) receptors on airway smooth muscle, inhibiting acetylcholine‑mediated bronchoconstriction. This blockade prevents calcium influx, leading to relaxation of the bronchial smooth muscle and increased airway diameter, thereby improving airflow and reducing respiratory resistance.

Adverse reactions may occur with inhaled ipratropium bromide. Most are mild and reversible, but rare serious events have been reported.

Common Side Effects

• Dry mouth: reduced salivation after inhalation.
• Cough: transient irritation of the airway.
• Throat irritation: mild soreness or discomfort.
• Hoarseness: temporary voice changes.
• Nasal congestion: mild blockage of nasal passages.
• Headache: occasional mild headache.

Serious or Rare Side Effects

• Paradoxical bronchospasm: worsening of airway obstruction.
• Allergic reactions: rash, itching, or swelling.
• Angioedema: swelling of lips, tongue, or face.
• Severe respiratory distress: difficulty breathing requiring medical attention.
• Cardiac arrhythmias: rare irregular heartbeats.
• Vision changes: blurred vision or eye irritation.

Use ipratropium bromide with caution in specific clinical situations and follow recommended handling procedures.

• Pregnancy: discuss potential risks with a healthcare professional before use.
• Breastfeeding: consider possible drug transfer to infant; consult a physician.
• Pediatric use: ensure proper technique with the unidose device for children.
• Pre‑existing glaucoma: monitor intra‑ocular pressure as anticholinergic effects may exacerbate.
• Cardiovascular disease: observe for any changes in heart rate or rhythm.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ipratropium bromide may interact with other medications that affect cholinergic pathways or respiratory function.

Major Interactions (Avoid)

• Beta‑agonists combined with high‑dose anticholinergics: may increase risk of cardiovascular side effects.
• Tricyclic antidepressants: additive anticholinergic burden.

Moderate Interactions (Monitor Closely):\n- Other inhaled bronchodilators (e.g., albuterol): monitor for synergistic bronchodilation.

• Antihistamines with anticholinergic properties: watch for excessive dryness.
• Muscarinic antagonists (e.g., tiotropium): assess cumulative anticholinergic effect.
• MAO inhibitors: potential for increased cholinergic side effects.
• Theophylline: monitor for altered respiratory response.